Trinity Biotech plc (TRIB)
Market Cap | 15.51M |
Revenue (ttm) | 56.71M |
Net Income (ttm) | -21.53M |
Shares Out | 7.64M |
EPS (ttm) | 4.25 |
PE Ratio | 0.48 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 39,807 |
Open | 2.030 |
Previous Close | 2.110 |
Day's Range | 2.030 - 2.190 |
52-Week Range | 1.490 - 5.500 |
Beta | 1.17 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 23, 2024 |
About TRIB
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and o... [Read more]
Financial Performance
In 2023, TRIB's revenue was $56.83 million, a decrease of -9.10% compared to the previous year's $62.52 million. Losses were -$24.02 million, -41.43% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/1/u/press3-2492376.jpg)
Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
![](https://cdn.snapi.dev/images/v1/6/y/press15-2471086.jpg)
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, i...
![](https://cdn.snapi.dev/images/v1/9/9/press4-2458309.jpg)
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
![](https://cdn.snapi.dev/images/v1/8/a/press12-2445253.jpg)
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO 1 on annualized revenues of approximately $75 million by Q2 2025-
![](https://cdn.snapi.dev/images/v1/p/l/conf17-2442386.jpg)
Trinity Biotech plc to Announce Q1 2024 Financial Results
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagno...
![](https://cdn.snapi.dev/images/v1/z/p/press4-2434885.jpg)
Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI
DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...
![](https://cdn.snapi.dev/images/v1/q/x/press8-2427498.jpg)
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales
DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...
![](https://cdn.snapi.dev/images/v1/m/v/press16-2418445.jpg)
Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...
![](https://cdn.snapi.dev/images/v1/k/w/press18-2356115.jpg)
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, includi...
![](https://cdn.snapi.dev/images/v1/2/k/conf14-2347489.jpg)
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical ...
![](https://cdn.snapi.dev/images/v1/4/i/press20-2315518.jpg)
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") ...
![](https://cdn.snapi.dev/images/v1/d/n/press20-2278813.jpg)
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depos...
![](https://cdn.snapi.dev/images/v1/y/u/press3-2273449.jpg)
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
DUBLIN, Ireland, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) repre...
![](https://cdn.snapi.dev/images/v1/1/e/conf18-2266909.jpg)
Trinity Biotech to Present at Emerging Growth Conference
DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March...
![](https://cdn.snapi.dev/images/v1/9/f/press9-2264387.jpg)
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for ...
![](https://cdn.snapi.dev/images/v1/n/k/press6-2252601.jpg)
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company's results for the quarter ended September 30, 2023. Business Updates and Strategic Pri...
![](https://cdn.snapi.dev/images/v1/w/y/press3-2252591.jpg)
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch ...
![](https://cdn.snapi.dev/images/v1/q/c/press12-2252581.jpg)
Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.
-Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management
![](https://cdn.snapi.dev/images/v1/a/d/press15-2251962.jpg)
Trinity Biotech plc to Host Investor Call
Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET
![](https://cdn.snapi.dev/images/v1/x/s/press20-2208952.jpg)
Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya
DUBLIN, Ireland, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical la...
![](https://cdn.snapi.dev/images/v1/f/c/press5-2200935.jpg)
Trinity Biotech Announces Management Changes
John Gillard Named Chief Executive Officer Des Fitzgerald Named Interim Chief Financial Officer DUBLIN, Ireland, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a...
![](https://cdn.snapi.dev/images/v1/9/q/press15-2174753.jpg)
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical l...
![](https://cdn.snapi.dev/images/v1/5/m/press1-2087684.jpg)
Trinity Biotech Announces Q2 2023 Financial Results
DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets...
![](https://cdn.snapi.dev/images/v1/o/4/conf3-2080390.jpg)
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
DUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will r...
![](https://cdn.snapi.dev/images/v1/k/f/press1-2058465.jpg)
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
DUBLIN, Ireland, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical ...